Negative Allosteric Modulation of mGluR5 Partially Corrects Pathophysiology in a Mouse Model of Rett Syndrome

Jifang Tao1,2, Hao Wu3,4,5, Amanda A Coronado1,2

  • 1Picower Institute for Learning and Memory and.

Insights

Rett syndrome (RTT) and fragile X share pathophysiology, with both conditions showing altered protein synthesis. Targeting metabotropic glutamate receptor 5 (mGluR5) in Mecp2 KO mice reduced abnormal gene expression and improved some RTT phenotypes.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the MECP2 gene, affecting epigenetic regulation.
  • Altered synaptic protein synthesis is implicated in intellectual disability and autism spectrum disorders.
  • Fragile X syndrome, another monogenic cause of intellectual disability, involves the loss of FMRP and excessive protein synthesis.

Purpose of the Study:

  • To investigate shared pathophysiology between RTT and fragile X syndrome.
  • To examine the role of metabotropic glutamate receptor 5 (mGluR5) and protein synthesis in RTT.
  • To identify MeCP2-regulated transcripts and their overlap with FMRP targets.

Main Methods:

  • Genome-wide profiling of ribosome-bound mRNAs in Mecp2 KO mouse hippocampal CA1 neurons.
  • Comparison of Mecp2 KO translatome with FMRP targets and SFARI autism genes.
  • Treatment of Mecp2 KO mice with mGluR5-negative allosteric modulators (NAMs).

Main Results:

  • Mecp2 KO mice exhibit altered mGluR5- and protein-synthesis-dependent synaptic plasticity.
  • Significant overlap exists between upregulated transcripts in Mecp2 KO mice and FMRP targets, often encoding synaptic function-related genes.
  • mGluR5 NAM treatment reduced aberrant mRNA levels and ameliorated some RTT phenotypes, including hippocampal cell size and lifespan.

Conclusions:

  • A mechanistic link exists between MeCP2 transcriptional regulation and mGluR5/FMRP translational regulation.
  • Shared pathways involving synaptic gene expression may underlie RTT and fragile X.
  • Targeting mGluR5 offers a potential therapeutic strategy for RTT by modulating protein synthesis.

Related Concept Videos